Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

RuQuan You

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|December 23, 2021
Innovative Pediatric Development for Secukinumab in Psoriasis: Faster Patient Access, Reduction of Patients on ControlRuquan You, Sebastian Weber, Bruno Bieth, et al.
Health & Place|November 27, 2012
Area level deprivation and drinking patterns among adolescentsMathilde Vinther-Larsen, Taisia Huckle, RuQuan You, et al.
Scientific Reports|November 10, 2022
Conjugate heat transfer study of various cooling structures and sensitivity analysis of overall cooling effectivenessRunzhou Liu, Haiwang Li, Ruquan You, et al.
Journal of the American Academy of Dermatology|October 7, 2016
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trialAlice Gottlieb, John Sullivan, Martijn van Doorn, et al.
Clinical and Experimental Dermatology|October 11, 2023
Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studiesMark Lebwohl, Lars Iversen, Liv Eidsmo, et al.
Journal of the American Academy of Dermatology|June 21, 2015
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialDiamant Thaçi, Andrew Blauvelt, Kristian Reich, et al.
The British Journal of Dermatology|January 4, 2022
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trialMatthias Augustin, Kristian Reich, Paul Yamauchi, et al.
Journal of the American Academy of Dermatology|September 25, 2016
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR studyAndrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, et al.
The British Journal of Dermatology|February 10, 2023
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trialsRichard G Langley, Howard Sofen, Ignacio Dei-Cas, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|December 23, 2021
Innovative Pediatric Development for Secukinumab in Psoriasis: Faster Patient Access, Reduction of Patients on ControlRuquan You, Sebastian Weber, Bruno Bieth, et al.
Health & Place|November 27, 2012
Area level deprivation and drinking patterns among adolescentsMathilde Vinther-Larsen, Taisia Huckle, RuQuan You, et al.
Scientific Reports|November 10, 2022
Conjugate heat transfer study of various cooling structures and sensitivity analysis of overall cooling effectivenessRunzhou Liu, Haiwang Li, Ruquan You, et al.
Journal of the American Academy of Dermatology|October 7, 2016
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trialAlice Gottlieb, John Sullivan, Martijn van Doorn, et al.
Clinical and Experimental Dermatology|October 11, 2023
Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studiesMark Lebwohl, Lars Iversen, Liv Eidsmo, et al.
Journal of the American Academy of Dermatology|June 21, 2015
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialDiamant Thaçi, Andrew Blauvelt, Kristian Reich, et al.
The British Journal of Dermatology|January 4, 2022
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trialMatthias Augustin, Kristian Reich, Paul Yamauchi, et al.
Journal of the American Academy of Dermatology|September 25, 2016
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR studyAndrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, et al.
The British Journal of Dermatology|February 10, 2023
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trialsRichard G Langley, Howard Sofen, Ignacio Dei-Cas, et al.
Pageof 1